

Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Drug Submission Status

Complete Streamlined Multiple-Source Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via the electronic Bulletin Board System (BBS).

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Sibutramine	Meridia	sibutramine	10mg	capsule	02337614
Apotex Inc.	Apo-Sibutramine	Meridia	sibutramine	15mg	capsule	02337622
Apotex Inc.	Apo-Tramadol/ Acet	Tramacet	tramadol HCl/ acetaminophen	37.5mg/ 325mg	FC tablet	02336790
Novopharm Ltd.	Novo-Olanzapine OD	Zyprexa Zydis	olanzapine ODT	20mg	OD tablet	02321386
Novopharm Ltd.	Novo-Naratriptan	Amerge	naratriptan	1mg	FC tablet	02314290
Novopharm Ltd.	Novo-Naratriptan	Amerge	naratriptan	2.5mg	FC tablet	02314304
Pharmel Inc.	Phl-Zopiclone	Imovane	zopiclone	5mg	FC tablet	02294052
Pharmel Inc.	Phl-Zopiclone	Imovane	zopiclone	7.5mg	FC tablet	02294060

Updated: February 4, 2010